Enterprise Value

111.5B

Cash

7.098B

Avg Qtr Burn

N/A

Short % of Float

1.47%

Insider Ownership

0.10%

Institutional Own.

86.85%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tecartus® (brexucabtagene autoleucel) (CAR-T) Details
Leukemia, B-cell acute lymphoblastic leukemia, Acute lymphoblastic leukemia

Approved

Quarterly sales

Trodelvy® (sacituzumab govitecan-hziy) Details
Cancer, Breast cancer, ER+/HER2- breast cancer

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Yescarta® Details
Lymphopenia, B-cell lymphoma

Approved

Quarterly sales

BLA

Resubmission

Phase 3

Update

Lenacapavir Details
Human immunodeficiency virus

Phase 2

Data readout

Etrumadenant Details
Colorectal cancer

Phase 2

Data readout

Yescarta Details
Lymphopenia, B-cell lymphoma

Phase 2

Interim update

Phase 2

Update

Magrolimab+Azacitidine Details
High risk myelodysplastic syndromes

Failed

Discontinued